Prostate Cancer

Prostate cancer ranks as the second most common cause of cancer-related deaths among men in the United States. Aggressive forms of this cancer are linked to mutations in homologous recombination repair genes. Read More ›

Despite recommendations, genetic testing for advanced prostate cancer is not widely used and may not be readily accepted by patients. This analysis investigated the attitudes and decisional conflicts surrounding genetic testing and the differences between White and non-White patients. Read More ›

Disparities have been extensively documented in prostate cancer screening uptake and shared decision-making conversations among racial and sexual minorities. Yet, the impact of racial/ethnic identity and sexual orientation on prostate-specific antigen testing uptake remains uncertain. Read More ›

The combination of cabozantinib and atezolizumab improved radiographic progression-free survival (rPFS) versus a switch to a second novel hormonal agent (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a first NHT, according to findings from the phase 3 CONTACT-02 trial. Read More ›

According to the American Cancer Society, approximately 288,300 men in the United States will be diagnosed with prostate cancer in 2023 and 34,700 deaths will be attributed to the disease. Read More ›

An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease, contributing to the evidence that this combination should be considered the new standard of care for this patient population. Read More ›

A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial. Read More ›

Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial, presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium. Read More ›

Treatment with the androgen receptor inhibitor darolutamide (Nubeqa), in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the New England Journal of Medicine. Read More ›

Two years of abiraterone acetate (Zytiga) plus prednisone added to androgen-deprivation therapy (ADT) improved metastasis-free survival and overall survival compared with ADT alone in men with nonmetastatic castration-sensitive prostate cancer, whereas the addition of enzalutamide (Xtandi) to ADT had no benefit, and much greater toxicity. Read More ›